ACVRL1 Protein (His tag)
-
- Antigène Voir toutes ACVRL1 Protéines
- ACVRL1 (Activin A Receptor Type II-Like 1 (ACVRL1))
- Type de proteíne
- Recombinant
- Activité biologique
- Active
-
Origine
- Humain
-
Source
- HEK-293 Cells
- Purification/Conjugué
- Cette ACVRL1 protéine est marqué à la His tag.
- Application
- Western Blotting (WB)
- Attributs du produit
-
Measured by its ability to inhibit BMP9 induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is typically 1-3 ng/mL in the presence of 2 ng/mL of rhBMP9.
- Pureté
- >97 % as determined by SDS-PAGE.
- Top Product
- Discover our top product ACVRL1 Protéine
-
-
- Indications d'application
- This recombinant protein can be used for WB. For research use only.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Buffer
- PBS, pH 7.4
- Stock
- -80 °C,-20 °C
- Stockage commentaire
- Lyophilized Protein should be stored at -20°C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20°C or -70°C. Avoid repeated freeze-thaw cycles.
-
- Antigène
- ACVRL1 (Activin A Receptor Type II-Like 1 (ACVRL1))
- Autre désignation
- ALK 1 (ACVRL1 Produits)
- Synonymes
- ACVRL1 Protein, vgb Protein, alk1 Protein, zehn1109 Protein, hm:zehn1109 Protein, ACVRLK1 Protein, ALK-1 Protein, ALK1 Protein, HHT Protein, HHT2 Protein, ORW2 Protein, SKR3 Protein, TSR-I Protein, R-3 Protein, R3 Protein, SETHKIR Protein, AI115505 Protein, AI427544 Protein, Acvrlk1 Protein, Alk1 Protein, activin A receptor like type 1 Protein, activin A receptor type II-like 1 Protein, activin A receptor, type II-like 1 Protein, ACVRL1 Protein, acvrl1 Protein, Acvrl1 Protein
- Sujet
- Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.
- Poids moléculaire
- 12.3 kDa
- ID gène
- 94
- NCBI Accession
- NP_000011
- UniProt
- P37023
-